EVIDENCE DESK / FOUR COMPOUNDS
A Calmer Read of Peptide Claims
KPV, NAD+, BPC-157, and GHK-Cu—measured findings separated from adverse signals, anecdotes, and questions the literature has not settled.
KPV
A three-amino-acid fragment with anti-inflammatory signals in cell and animal models, but no published human clinical trial.
Read the KPV file →
NAD+
A core cellular coenzyme whose precursors reliably raise blood NAD+, while hard human outcomes remain inconsistent.
Read the NAD+ file →
BPC-157
A fifteen-amino-acid research peptide with extensive animal repair findings and only a very small human evidence base.
Read the BPC-157 file →
GHK-Cu
A copper-binding tripeptide studied mainly in skin biology, with modest topical human evidence and broad preclinical claims.
Read the GHK-Cu file →The short version
Peaceful Peptides is a reading desk for four compounds that are often discussed together but do not share the same kind of evidence. KPV is a short peptide studied mainly in inflammation models. NAD+ is a coenzyme already present in cells; most human intervention studies test its precursors, not the intact molecule. BPC-157 is an experimental repair peptide supported largely by animal work. GHK-Cu is a copper-bound peptide with its clearest human research in topical skin and hair settings.
The key question is not whether a claim sounds plausible. It is what was measured, in which model, against what comparison, and with what uncertainty. A cell experiment can clarify a pathway. An animal study can test a biological idea. Neither proves a human benefit. A small human trial is useful, but it cannot carry the certainty of a large, replicated trial. This digest keeps those levels visible, reports adverse findings beside benefits, and leaves unresolved questions unresolved. It is independent editorial analysis, not a product catalogue or medical guidance.
Four files, four evidence profiles
The shared theme is research fundamentals, not a shared therapeutic category. KPV anchors the desk because it shows why formulation and model choice matter: cell and mouse studies connect its uptake to the PepT1 transporter and its activity to inflammatory signaling, while no published human trial establishes efficacy or safety [1][2][3][4]. NAD+ offers a different lesson. Human studies show that precursor supplementation can raise blood NAD+, yet a recent review found that clinical efficacy and tissue-specific data remain limited [8].
BPC-157 demonstrates the gap between a large preclinical reputation and a very small clinical record. Its first human safety pilot involved only two healthy adults and did not test efficacy [13]. GHK-Cu has more direct human-facing material, but the best signals are small topical studies or reviews, and delivery through the skin remains a central limitation [18][20][22].
That spread is useful. It prevents the word peptide from doing more explanatory work than it should. The comparison matrix evaluates each compound by model, endpoint, and evidence maturity rather than treating them as interchangeable candidates.
What are research peptides?
A peptide is a short chain of amino acids, the building blocks of proteins. Length alone does not determine function. KPV has three amino acids; BPC-157 has fifteen. GHK-Cu is also a three-amino-acid sequence, but its copper ion is integral to the complex described in much of the literature. NAD+ is the outlier on this desk: it is a dinucleotide coenzyme, not a peptide, included because it occupies the same research-and-wellness claims landscape and rewards the same evidence checks.
“Research peptide” is also a context label, not proof of quality or usefulness. It can describe material used in laboratory experiments, an unapproved compound, or a subject of early translational work. The label does not supply human pharmacokinetics, controlled outcomes, product identity, or regulatory approval. Those have to be established separately.
The safest reading order is simple: identify the experimental model; name the measured endpoint; note the comparator; then ask whether the result has been reproduced in people. On this desk, the answers range from molecular signaling and rodent disease models to small controlled topical studies. That range is the story—not a detail to smooth over.
How claims are checked here
Each claim is assigned to the evidence that can actually support it. Mechanism describes a pathway, not a clinical outcome. A surrogate such as blood NAD+ is reported as a biomarker, not automatically as longer life or disease prevention. A result from rabbit corneas remains a rabbit-cornea result, even when the endpoint is striking [6]. A combination product containing GHK is not treated as a pure GHK-Cu trial [20].
Quantitative results are cited at the point of use. Community reports appear only as anecdotal, not clinical evidence, and they never establish efficacy or safety. Regulatory status is kept separate from biological plausibility. Finally, absence of a reported adverse event in a tiny study is not treated as proof of safety; it is simply what that study observed. That quiet separation—benefit, adverse finding, open question—is the editorial method behind every page.